Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma
AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patien...
Saved in:
Published in | World journal of gastroenterology : WJG Vol. 20; no. 8; pp. 2098 - 2106 |
---|---|
Main Author | |
Format | Journal Article |
Language | English |
Published |
United States
Baishideng Publishing Group Co., Limited
28.02.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patients,38(42%)experienced recurrence within two years of surgery.To adjust for baseline differences between this early recurrence group and the other patients,propensity-score matching was used to generate 25 pairs of patients.Immunohistochemistry was used to compare expression of CD133,CD90,and epithelial cell adhesion molecule(EpCAM)in liver tissues from propensity score-matched patients and from 10 healthy adults.Associations of the three markers with HCC,clinicopathological characteristics,early recurrence,and survival time were explored.RESULTS:The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue(P<0.001 for all).Among the HCC clinicopathology characteristics examined,the absence of tumor capsule was associated with CD133 expression(P=0.005);higher histopathology grade and larger tumor size were associated with CD90 expression(P=0.010 and 0.034,respectively);and elevated serum alpha-fetoprotein levels were associated with EpCAM expression(P=0.021).Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients(P=0.001 and 0.045,respectively),whereas CD133 expression was not significantly different between the two groups(P=0.440).Multivariate analysis identified only CD90 expression as significantly associated with early recurrence.Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients.Cox regression identified EpCAM expression as an independent predictor of survival time.CONCLUSION:Expression of CD133,CD90,and EpCAM CSC markers may be linked to HCC tumor onset and/or progression.In addition,EpCAM expression is associated with shorter survival time,while CD90 expression is associated with early HCC recurrence. |
---|---|
AbstractList | To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.
A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored.
The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time.
Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence. AIM: To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients. METHODS: A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored. RESULTS: The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue ( P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression ( P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression ( P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression ( P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients ( P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups ( P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time. CONCLUSION: Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence. AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular carcinoma(HCC)patients.METHODS:A consecutive series of 90 HCC patients who underwent curative hepatectomy between April2007 and April 2009 were analyzed.Of the 90 patients,38(42%)experienced recurrence within two years of surgery.To adjust for baseline differences between this early recurrence group and the other patients,propensity-score matching was used to generate 25 pairs of patients.Immunohistochemistry was used to compare expression of CD133,CD90,and epithelial cell adhesion molecule(EpCAM)in liver tissues from propensity score-matched patients and from 10 healthy adults.Associations of the three markers with HCC,clinicopathological characteristics,early recurrence,and survival time were explored.RESULTS:The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue(P<0.001 for all).Among the HCC clinicopathology characteristics examined,the absence of tumor capsule was associated with CD133 expression(P=0.005);higher histopathology grade and larger tumor size were associated with CD90 expression(P=0.010 and 0.034,respectively);and elevated serum alpha-fetoprotein levels were associated with EpCAM expression(P=0.021).Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients(P=0.001 and 0.045,respectively),whereas CD133 expression was not significantly different between the two groups(P=0.440).Multivariate analysis identified only CD90 expression as significantly associated with early recurrence.Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients.Cox regression identified EpCAM expression as an independent predictor of survival time.CONCLUSION:Expression of CD133,CD90,and EpCAM CSC markers may be linked to HCC tumor onset and/or progression.In addition,EpCAM expression is associated with shorter survival time,while CD90 expression is associated with early HCC recurrence. To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.AIMTo investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.A consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored.METHODSA consecutive series of 90 HCC patients who underwent curative hepatectomy between April 2007 and April 2009 were analyzed. Of the 90 patients, 38 (42%) experienced recurrence within two years of surgery. To adjust for baseline differences between this early recurrence group and the other patients, propensity-score matching was used to generate 25 pairs of patients. Immunohistochemistry was used to compare expression of CD133, CD90, and epithelial cell adhesion molecule (EpCAM) in liver tissues from propensity score-matched patients and from 10 healthy adults. Associations of the three markers with HCC, clinicopathological characteristics, early recurrence, and survival time were explored.The expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time.RESULTSThe expression of all three CSC markers was significantly higher in HCC tissue than in healthy liver tissue (P < 0.001 for all). Among the HCC clinicopathology characteristics examined, the absence of tumor capsule was associated with CD133 expression (P = 0.005); higher histopathology grade and larger tumor size were associated with CD90 expression (P = 0.010 and 0.034, respectively); and elevated serum alpha-fetoprotein levels were associated with EpCAM expression (P = 0.021). Expression of CD90 and EpCAM was significantly higher in the early recurrence group than in other patients (P = 0.001 and 0.045, respectively), whereas CD133 expression was not significantly different between the two groups (P = 0.440). Multivariate analysis identified only CD90 expression as significantly associated with early recurrence. Log-rank analysis identified expression of both CD90 and EpCAM as significantly associated with survival time of HCC patients. Cox regression identified EpCAM expression as an independent predictor of survival time.Expression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence.CONCLUSIONExpression of CD133, CD90, and EpCAM CSC markers may be linked to HCC tumor onset and/or progression. In addition, EpCAM expression is associated with shorter survival time, while CD90 expression is associated with early HCC recurrence. |
Author | Zhe Guo Le-Qun Li Jing-Hang Jiang Chao Ou Li-Xia Zeng Bang-De Xiang |
AuthorAffiliation | Department of Hepatobiliary Surgery,Tumor Hospital of Guangxi Medical University Department of Clinical Laboratory,Tumor Hospital of Guangxi Medical University Department of Pathology,Tumor Hospital of Guangxi Medical University |
Author_xml | – sequence: 1 givenname: Zhe surname: Guo fullname: Guo, Zhe |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24616575$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtr3DAUhUVJaSZp190VLbvx5OplS5tCGfqCQDftWijy9YxSjzSR7An595XJJLSFCoRAOt85XJ0LchZTRELeMliLTuqr-9vt-shhHfSag9EvyIpzZhquJZyRFQPoGiN4d04uSrkF4EIo_oqcc9myVnVqRdzGRY-Zlgn31OM40r3LvzAX6lPOOLoJ6X2YdhRdHh9oRj_X64pQF3ta5nwMRzfSEOkOD25Ki8U8uky9yz7EtHevycvBjQXfnM5L8vPzpx-br8319y_fNh-vGy9FNzVDOygGDJDDoNuOsR5VhyhbZOAEk23XixupYRDC6FabqjNQNbIHJYUYxCX58Oh7mG_22HuMU3ajPeRQJ3qwyQX790sMO7tNRyuMkFKzavD-ZJDT3YxlsvtQlnlcxDQXyxS0nTZa8ip992fWc8jTv1aBehT4nErJOFgfJjeFtESH0TKwS3-29mdrfzZou_RXuat_uCfr_xPiROxS3N6FuH1GDOhlGQVSS6O41KqtGxQTvwFn9a-N |
CitedBy_id | crossref_primary_10_1038_cddis_2015_241 crossref_primary_10_18632_oncotarget_19000 crossref_primary_10_1007_s13277_016_4915_3 crossref_primary_10_1186_s12957_016_1028_9 crossref_primary_10_1186_s12967_020_02243_w crossref_primary_10_3892_ol_2018_8666 crossref_primary_10_1155_2021_5546032 crossref_primary_10_1016_j_ijsu_2018_06_025 crossref_primary_10_1097_PAI_0000000000000840 crossref_primary_10_18632_oncotarget_10750 crossref_primary_10_3390_cancers16101831 crossref_primary_10_18097_PBMC20166203228 crossref_primary_10_1097_MD_0000000000001306 crossref_primary_10_1124_jpet_123_001898 crossref_primary_10_1007_s11605_020_04611_9 crossref_primary_10_1002_dvdy_24242 crossref_primary_10_3748_wjg_v24_i35_4000 crossref_primary_10_3390_cells9061331 crossref_primary_10_1097_01_XEJ_0000534710_66241_04 crossref_primary_10_3390_cells9041020 crossref_primary_10_1111_cas_13415 crossref_primary_10_1186_s12943_015_0426_x crossref_primary_10_1007_s12672_025_02095_0 crossref_primary_10_1093_jjco_hyx157 crossref_primary_10_1016_j_livres_2023_07_003 crossref_primary_10_1016_j_amjsurg_2015_12_019 crossref_primary_10_18632_oncoscience_163 crossref_primary_10_1002_mc_22532 crossref_primary_10_1097_PAS_0000000000001990 crossref_primary_10_1016_j_tranon_2021_101073 crossref_primary_10_3390_medicina58020212 crossref_primary_10_4081_oncol_2020_452 crossref_primary_10_1016_j_bbrc_2020_03_009 crossref_primary_10_1111_jcmm_18295 crossref_primary_10_1016_j_biocel_2016_06_004 crossref_primary_10_3389_fonc_2020_572861 crossref_primary_10_18632_oncotarget_22078 crossref_primary_10_3748_wjg_v21_i42_12190 crossref_primary_10_18632_oncotarget_10807 crossref_primary_10_1007_s13277_015_3487_y crossref_primary_10_5009_gnl18345 crossref_primary_10_1097_MD_0000000000001806 crossref_primary_10_3389_fonc_2023_1242231 crossref_primary_10_1111_his_13520 crossref_primary_10_3727_096504020X15919605976853 crossref_primary_10_1002_med_21967 crossref_primary_10_2217_epi_15_23 crossref_primary_10_1016_j_ajg_2020_04_002 crossref_primary_10_1080_0284186X_2019_1657940 crossref_primary_10_3892_ol_2016_4343 crossref_primary_10_18632_oncotarget_9116 crossref_primary_10_1134_S1990750817010036 crossref_primary_10_3390_cells9122672 crossref_primary_10_1007_s00595_020_01968_x crossref_primary_10_1155_2018_5970852 crossref_primary_10_3892_ol_2016_4547 crossref_primary_10_3748_wjg_v25_i14_1653 crossref_primary_10_2147_OTT_S298576 crossref_primary_10_4254_wjh_v7_i1_7 crossref_primary_10_1016_j_talanta_2021_122817 crossref_primary_10_1186_s12967_015_0609_7 crossref_primary_10_1093_carcin_bgx050 crossref_primary_10_1007_s10620_019_05844_8 crossref_primary_10_1186_s13046_019_1442_2 crossref_primary_10_1016_j_clinre_2021_101664 crossref_primary_10_3390_ijms24021417 |
ContentType | Journal Article |
Copyright | 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014 |
Copyright_xml | – notice: 2014 Baishideng Publishing Group Co., Limited. All rights reserved. 2014 |
DBID | 2RA 92L CQIGP W91 ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
DOI | 10.3748/wjg.v20.i8.2098 |
DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
DocumentTitleAlternate | Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma |
EISSN | 2219-2840 |
EndPage | 2106 |
ExternalDocumentID | PMC3934481 24616575 10_3748_wjg_v20_i8_2098 90888889504849524856485051 |
Genre | Research Support, Non-U.S. Gov't Journal Article Observational Study |
GroupedDBID | --- 123 29R 2B. 2C~ 2RA 2WC 36B 53G 5VR 8WL 92F 92I 92L 93N 93R AAKDD ACGFO AENEX AFUIB ALMA_UNASSIGNED_HOLDINGS CCEZO CHBEP CIEJG CQIGP CS3 CW9 DIK DU5 E3Z EBS EJD EMB F5P FA0 FRP GX1 HYE M~E OK1 P2P RNS RPM SV3 TCJ TGQ TR2 W91 WFFXF XSB ~WA AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
ID | FETCH-LOGICAL-c437t-f6f51010e20f86711de57ee46e10a31467d3b480f3398689e2090de54d05433f3 |
ISSN | 1007-9327 2219-2840 |
IngestDate | Thu Aug 21 18:11:55 EDT 2025 Fri Jul 11 11:42:48 EDT 2025 Mon Jul 21 05:50:35 EDT 2025 Thu Apr 24 22:53:21 EDT 2025 Tue Jul 01 01:53:29 EDT 2025 Wed Feb 14 10:28:37 EST 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 8 |
Keywords | Epithelial cell adhesion molecule Hepatocellular carcinoma Cancer stem cells CD90 CD133 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c437t-f6f51010e20f86711de57ee46e10a31467d3b480f3398689e2090de54d05433f3 |
Notes | Zhe Guo;Le-Qun Li;Jing-Hang Jiang;Chao Ou;Li-Xia Zeng;Bang-De Xiang;Department of Hepatobiliary Surgery,Tumor Hospital of Guangxi Medical University;Department of Clinical Laboratory,Tumor Hospital of Guangxi Medical University;Department of Pathology,Tumor Hospital of Guangxi Medical University ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Telephone: +86-771-5330968 Fax: +86-771-5312000 Correspondence to: Bang-De Xiang, PhD, Department of Hepatobiliary Surgery, Tumor Hospital of Guangxi Medical University, He Di Rd. 71, Nanning 530021, Guangxi Zhuang Autonomous Region, China. xiaopushu-213@163.com Author contributions: Xiang BD designed the research; Guo Z and Li LQ performed the research; Jiang JH and Guo Z evaluated the clinic records and performed the statistical analysis; Ou C and Zeng LX performed the immunohistochemistry experiment; Guo Z wrote the manuscript; all authors have read and approved the final manuscript. |
OpenAccessLink | https://www.wjgnet.com/1007-9327/full/v20/i8/2098.htm |
PMID | 24616575 |
PQID | 1506789842 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3934481 proquest_miscellaneous_1506789842 pubmed_primary_24616575 crossref_citationtrail_10_3748_wjg_v20_i8_2098 crossref_primary_10_3748_wjg_v20_i8_2098 chongqing_primary_90888889504849524856485051 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2014-02-28 |
PublicationDateYYYYMMDD | 2014-02-28 |
PublicationDate_xml | – month: 02 year: 2014 text: 2014-02-28 day: 28 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | World journal of gastroenterology : WJG |
PublicationTitleAlternate | World Journal of Gastroenterology |
PublicationYear | 2014 |
Publisher | Baishideng Publishing Group Co., Limited |
Publisher_xml | – name: Baishideng Publishing Group Co., Limited |
References | 15567937 - Breast Cancer Res Treat. 2004 Aug;86(3):207-13 16678891 - Gynecol Oncol. 2006 Nov;103(2):483-8 7509044 - Nature. 1994 Feb 17;367(6464):645-8 21259248 - J Surg Oncol. 2011 Feb;103(2):148-51 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 17122772 - Nature. 2007 Jan 4;445(7123):106-10 19747749 - J Hepatol. 2009 Nov;51(5):890-7 19018978 - Liver Int. 2009 May;29(5):736-42 9802183 - Stat Med. 1998 Oct 15;17(19):2265-81 16256907 - J Am Coll Surg. 2005 Nov;201(5):663-70 20925139 - Pharm Stat. 2011 Mar-Apr;10(2):150-61 12409666 - Ann Surg. 2002 Nov;236(5):602-11 17952444 - Pediatr Surg Int. 2008 Jan;24(1):101-5 22161900 - J Surg Oncol. 2012 Jan;105(1):85-90 18275073 - Hepatology. 2008 Mar;47(3):919-28 23180689 - Int J Cancer. 2013 Jun 15;132(12):2948-55 18285265 - Am J Clin Pathol. 2008 Mar;129(3):424-9 14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8 15888687 - Stem Cells. 2005 Aug;23(7):879-94 17600130 - Am J Pathol. 2007 Aug;171(2):386-95 19150350 - Gastroenterology. 2009 Mar;136(3):1012-24 19711346 - Int J Cancer. 2010 May 1;126(9):2067-78 23504121 - Ann Surg Oncol. 2013 Aug;20(8):2526-33 21374666 - Hepatology. 2011 Mar;53(3):1020-2 22799330 - Asian Pac J Cancer Prev. 2012;13(4):1349-53 18172261 - Clin Cancer Res. 2008 Jan 1;14(1):123-9 9356465 - Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 17097610 - Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 17211480 - Br J Cancer. 2007 Feb 12;96(3):417-23 17673212 - Gastroenterology. 2007 Sep;133(3):937-50 11259604 - Mol Cell Biol. 2001 Apr;21(7):2570-80 16076007 - Surgeon. 2005 Jun;3(3):210-5 11689955 - Nature. 2001 Nov 1;414(6859):105-11 22237392 - Nat Rev Cancer. 2012 Feb;12(2):133-43 22080056 - Mod Pathol. 2012 Mar;25(3):456-64 17122771 - Nature. 2007 Jan 4;445(7123):111-5 20602260 - Ann Surg Oncol. 2010 Dec;17(12):3137-44 15608167 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D154-9 18923165 - N Engl J Med. 2008 Nov 6;359(19):1995-2004 19190964 - Ann Surg Oncol. 2009 Apr;16(4):792-4 17585167 - Stem Cells. 2007 Oct;25(10):2575-82 18356041 - Curr Opin Genet Dev. 2008 Feb;18(1):48-53 19136966 - Nat Cell Biol. 2009 Feb;11(2):162-71 19583834 - J Transl Med. 2009;7:56 10077043 - Ann Surg. 1999 Mar;229(3):322-30 |
References_xml | – reference: 17211480 - Br J Cancer. 2007 Feb 12;96(3):417-23 – reference: 18923165 - N Engl J Med. 2008 Nov 6;359(19):1995-2004 – reference: 19018978 - Liver Int. 2009 May;29(5):736-42 – reference: 17600130 - Am J Pathol. 2007 Aug;171(2):386-95 – reference: 19583834 - J Transl Med. 2009;7:56 – reference: 17122771 - Nature. 2007 Jan 4;445(7123):111-5 – reference: 10077043 - Ann Surg. 1999 Mar;229(3):322-30 – reference: 19150350 - Gastroenterology. 2009 Mar;136(3):1012-24 – reference: 19747749 - J Hepatol. 2009 Nov;51(5):890-7 – reference: 22799330 - Asian Pac J Cancer Prev. 2012;13(4):1349-53 – reference: 12409666 - Ann Surg. 2002 Nov;236(5):602-11 – reference: 16678891 - Gynecol Oncol. 2006 Nov;103(2):483-8 – reference: 18356041 - Curr Opin Genet Dev. 2008 Feb;18(1):48-53 – reference: 18275073 - Hepatology. 2008 Mar;47(3):919-28 – reference: 15567937 - Breast Cancer Res Treat. 2004 Aug;86(3):207-13 – reference: 17585167 - Stem Cells. 2007 Oct;25(10):2575-82 – reference: 16256907 - J Am Coll Surg. 2005 Nov;201(5):663-70 – reference: 17122772 - Nature. 2007 Jan 4;445(7123):106-10 – reference: 19136966 - Nat Cell Biol. 2009 Feb;11(2):162-71 – reference: 11689955 - Nature. 2001 Nov 1;414(6859):105-11 – reference: 21259248 - J Surg Oncol. 2011 Feb;103(2):148-51 – reference: 22161900 - J Surg Oncol. 2012 Jan;105(1):85-90 – reference: 22080056 - Mod Pathol. 2012 Mar;25(3):456-64 – reference: 9356465 - Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12425-30 – reference: 9802183 - Stat Med. 1998 Oct 15;17(19):2265-81 – reference: 22237392 - Nat Rev Cancer. 2012 Feb;12(2):133-43 – reference: 19190964 - Ann Surg Oncol. 2009 Apr;16(4):792-4 – reference: 19711346 - Int J Cancer. 2010 May 1;126(9):2067-78 – reference: 17097610 - Biochem Biophys Res Commun. 2006 Dec 29;351(4):820-4 – reference: 18172261 - Clin Cancer Res. 2008 Jan 1;14(1):123-9 – reference: 21296855 - CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 – reference: 7509044 - Nature. 1994 Feb 17;367(6464):645-8 – reference: 18285265 - Am J Clin Pathol. 2008 Mar;129(3):424-9 – reference: 23504121 - Ann Surg Oncol. 2013 Aug;20(8):2526-33 – reference: 21374666 - Hepatology. 2011 Mar;53(3):1020-2 – reference: 11259604 - Mol Cell Biol. 2001 Apr;21(7):2570-80 – reference: 17673212 - Gastroenterology. 2007 Sep;133(3):937-50 – reference: 17952444 - Pediatr Surg Int. 2008 Jan;24(1):101-5 – reference: 15888687 - Stem Cells. 2005 Aug;23(7):879-94 – reference: 14522905 - Cancer Res. 2003 Sep 15;63(18):5821-8 – reference: 15608167 - Nucleic Acids Res. 2005 Jan 1;33(Database issue):D154-9 – reference: 23180689 - Int J Cancer. 2013 Jun 15;132(12):2948-55 – reference: 20602260 - Ann Surg Oncol. 2010 Dec;17(12):3137-44 – reference: 20925139 - Pharm Stat. 2011 Mar-Apr;10(2):150-61 – reference: 16076007 - Surgeon. 2005 Jun;3(3):210-5 |
SSID | ssj0023352 |
Score | 2.3799117 |
Snippet | AIM:To investigate whether expression of cancer stem cell(CSC)markers is associated with recurrence and survival in hepatocellular... To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients. A... To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.AIMTo... AIM: To investigate whether expression of cancer stem cell (CSC) markers is associated with recurrence and survival in hepatocellular carcinoma (HCC) patients.... |
SourceID | pubmedcentral proquest pubmed crossref chongqing |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 2098 |
SubjectTerms | AC133 Antigen Adult Antigens, CD - metabolism Antigens, Neoplasm - metabolism Brief Cancer carcinoma Carcinoma, Hepatocellular - pathology Carcinoma, Hepatocellular - surgery Case-Control Studies CD133 Cell Adhesion Molecules - metabolism cells Cohort Studies Disease Progression Epithelial Cell Adhesion Molecule Follow-Up Studies Glycoproteins - metabolism Hepatectomy Hepatocellular Humans Immunohistochemistry Liver - metabolism Liver Neoplasms - pathology Liver Neoplasms - surgery Middle Aged Neoplasm Recurrence, Local Neoplastic Stem Cells - cytology Peptides - metabolism Prognosis stem Thy-1 Antigens - metabolism Treatment Outcome |
Title | Cancer stem cell markers correlate with early recurrence and survival in hepatocellular carcinoma |
URI | http://lib.cqvip.com/qk/84123X/201408/90888889504849524856485051.html https://www.ncbi.nlm.nih.gov/pubmed/24616575 https://www.proquest.com/docview/1506789842 https://pubmed.ncbi.nlm.nih.gov/PMC3934481 |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELaq5cIFgXiVl4zEAamkpLGT2EdUAVUFCKRdseISJanTFu0mJU0WiR_Fb2TGdty0u0iwlRq1qe2oni-eR8bfEPIiiBdMBQrub7AGPCx176UyzD0W-QXPfRXyTGf5fopmJ3x-Gp4OBr97WUttk43zX1fuK7mOVOEcyBV3yf6HZN2gcAI-g3zhCBKG4z_JeIoiq0fIxTzCCPzoHJNt6u0ox5obZ2BGmjir0izGNYbWDamsjpa3sEpcaM4NMBc34HzjEDorNccCQ2Vll2xrupq0mx7TxDLdNnWFnJ61IXLC6MLXuSvW9b7VYdhvK4edD2YrtvK-tA6T87WNWM9BiXqz1GpSjPu2Nh-g6ocmJry31VvH37CANJZGXV6KqcFqNzaBh4NdXJi04YFNGfdX6MDvIVH0l1vflLC2qhvc1-gqtYAUOyDLn9-X44vAH68xpc907IFkc65Rgvx6-DBqpx9d1uLnj1MmGfiz4G3fCMAtYV10yDr4uH9NP123_8FQSeHVXx9cGzmo7YWQ1GNVlcsfMDn7xtElj-cwcbdnCR3fJresC0PfGDzeIQNV3iWpwSJFLFIEErVYpA6LFLFINRbpDosUsEg7LNJ1SfexSB0W75GTd2-PpzPPlu_wcs7ixiuiAhd8XwV-gSyKk4UKY6V4pCZ-ylBDL1jGhV8wJkUkJLSTPrThC3AjGCvYfXJUVqV6SKiUhRAZeAIq4zzP4GsueC6LTIC7vAjTIXnl5jDZGJqWBDP44CVDUFJchsjdF8EbtNCQjLtpTnJLhY8VWc4ScIlRXAmIKwFxJWuRoLiG5KXr0A3_16bPO7klsFLjbKWlqtptglyesZCCB0PywMjRDdaBYUjiPQm7BsgCv_9LuV5pNngLyUfX7vmY3NzdvE_IUVO36ilY2k32TMP7D2gv1zs |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cancer+stem+cell+markers+correlate+with+early+recurrence+and+survival+in+hepatocellular+carcinoma&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Guo%2C+Zhe&rft.au=Li%2C+Le-Qun&rft.au=Jiang%2C+Jing-Hang&rft.au=Ou%2C+Chao&rft.date=2014-02-28&rft.pub=Baishideng+Publishing+Group+Co.%2C+Limited&rft.issn=1007-9327&rft.volume=20&rft.issue=8&rft.spage=2098&rft.epage=2106&rft_id=info:doi/10.3748%2Fwjg.v20.i8.2098&rft_id=info%3Apmid%2F24616575&rft.externalDocID=PMC3934481 |
thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F84123X%2F84123X.jpg |